Mesenchymal stromal cells for therapeutic neovascularization and cardiac repair
Jens Kastrup - University Hospital Rigshospitalet Copenhagen (Sub-project 7)
Angiogenesis Research Programme Cardiac Catheterization Laboratory 2014 The Heart Centre University Hospital Rigshospitalet 9, Blegdamsvej 2100 Copenhagen, Denmark Phone: +45 3545 2819 FAX: +45 3545 2705 e-Mail: jkastrup@rh.regionh.dk Website: http://www.rigshospitalet.dk/
It is not known, which cell markers are the best to control and describe the different steps in the development of human mesenchymal stromal cells into tissue specific cell types. MSC’s are normally characterized by the expression of specific surface markers and to be negative for the haematopoietic cell surface markers. However, these cell markers are not specific for MSC’s alone. Therefore, it is important to try to detect more specific cell markers, which can be used to control that the cell population is homogenous during isolation and culture expansion. Moreover, it is unknown whether the characterization and differentiation of human MSC’s from the bone marrow and adipose tissue is identical in healthy and cardiac patients, and whether the cells differentiate into endothelial precursor cells (EPC) and cardiomyocytes. In addition little is known about spontaneous differentiation of MSC’s during cultivation for clinical use. These questions will be evaluated by micro-DNA analyses, flow cytometry, immunohistochemistry and real-time PCR analyses.
In this project, focus will be on using human stem cells from bone marrow and also adipose tissue and establishing culture conditions, which can be approved for later clinical trials.
Fig. 1: Mesenchymal stromal cells from bone marrow and adipose tissue for endothelial and cardiomyocyte differentiation.